Search company, investor...

Founded Year

1945

Stage

IPO - II | IPO

About Alcon

Alcon (SIX/NYSE: ALC) develops, manufactures, and markets pharmaceuticals, surgical equipment, and devices. It provides contact lenses and other vision care products. Alcon also helps people to get rid of certain diseases, such as presbyopia, and dry eye, and also helps people who are blind from cataracts. The company was founded in 1945 and is based in Fort Worth, Texas.

Headquarters Location

6201 South Freeway

Fort Worth, Texas, 76134,

United States

800-862-5266

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Alcon Patents

Alcon has filed 1562 patents.

The 3 most popular patent topics include:

  • Ophthalmology
  • Eye surgery
  • Vision
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/28/2019

9/19/2023

Eye surgery, Ophthalmology, Medical equipment, Vision, Implants (medicine)

Grant

Application Date

6/28/2019

Grant Date

9/19/2023

Title

Related Topics

Eye surgery, Ophthalmology, Medical equipment, Vision, Implants (medicine)

Status

Grant

Latest Alcon News

Choose extended depth of focus IOL that will have best results with fewest compromises

Sep 22, 2023

Disclosures: Devgan reports owning CataractCoach.com, which is a free teaching website. Devgan reports previously serving as a consultant, advisor and speaker for the IOL manufacturers named in this article, Alcon, AMO/Johnson & Johnson and Bausch + Lomb, although he elects not to do so presently. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Our goal in cataract surgery is to restore vision to our patients and also to tailor the results to their needs. While some patients would be very happy with a monofocal IOL and a target of great distance vision while using reading glasses for near work, some patients have a strong desire to lessen their dependence on spectacles. The two primary designs for giving patients a wider range of vision without glasses are multifocal IOLs and extended depth of focus (EDOF) IOLs, each having their own benefits and compromises. 1. An eye set to plano (emmetropia) with a traditional monofocal IOL provides great distance vision but without near vision extension. If we aim this same monofocal IOL for a postop target of myopia, we can deliver near vision without glasses but not distance vision. Patients with astigmatism and mild myopia can have a wide range of vision naturally, but this comes at the expense of image quality. An ideal EDOF IOL would have a wide range without any compromises; however, this is not achievable with current technology. Source: Uday Devgan, MD Uday Devgan Multifocal IOL designs, typically trifocal or bifocal in nature, split the incoming light using diffractive optics, thereby providing a wide range of vision with a near addition of up to 3.5 D. This allows vision from far distance to as close as 30 cm (12 inches) without glasses, provided that there is sufficient illumination. The compromise is that this splitting of light into multiple zones decreases contrast and induces glare/halos, particularly at night. EDOF IOLs aim to lessen the compromises of these multifocal IOL designs but, as a result, produce less range without glasses, typically about 1.5 D. This allows vision from far distance to as close as 67 cm (26 inches) without glasses. If used in a mild monovision approach with one eye at emmetropia and the other eye at –1 D, this can be extended to a binocular range of 2.5 D, which brings the near point closer to about 40 cm (16 inches). Because residual astigmatism can also increase the depth of field, we compare these EDOF models in eyes with emmetropia and no residual cylinder (Figure 1). The three main EDOF IOL designs available in the U.S. are small aperture, diffractive optics and beam shaping. Small aperture EDOF IOLs The small aperture EDOF IOL that we have is the AcuFocus IC-8 Apthera (Bausch + Lomb), which was FDA approved in 2022. The original AcuFocus product was an intracorneal inlay for the treatment of presbyopia, and it was also relatively easy to integrate into a concomitantly performed LASIK procedure with a thick enough corneal flap. Many patients enjoyed the benefits of this inlay, but some had difficulties with the cornea accepting the foreign object. The optical engineers then incorporated this same small aperture concept to intra-IOL placement where it would likely pose no issues for long-term implantation. The IC-8 Apthera has a 6-mm optic with a central donut filter ring that has an outside diameter of 3.23 mm and a central zone of 1.36 mm in diameter (Figure 2). This makes the effective pupil size in most lighting conditions very small and takes advantage of this pinhole effect. The upside is that the range of vision increases dramatically, much like using a small aperture on a camera (such as f-stop f/22), which provides a wide field of view in sharp focus. This can also be beneficial in some cases in which irregular corneas from prior radial keratotomy or ectasia cause optical aberrations. The downside of this pinhole pupil is that much of the incoming light is lost. In bright daylight, this is virtually unnoticeable; however, in dim lighting conditions such as driving at night, there is a significant loss of illumination. For this reason, the labeling of this IOL recommends only unilateral implantation in the nondominant eye while the fellow eye receives a traditional monofocal IOL set to emmetropia. 2. The Bausch + Lomb AcuFocus IC-8 Apthera uses a filtering ring to limit the effective pupil size to 1.36 mm in order to extend the range, but there is loss of light and contrast, particularly at night. Diffractive ring EDOF IOLs The Johnson & Johnson Tecnis Symfony (formerly AMO, then Abbott) uses a series of diffractive rings on the optic to expand the range of vision without glasses. This design was approved in 2016 and has a good track record of providing less reliance on reading glasses, particularly for the intermediate range of 67 cm (26 inches). Successive diffractive rings split the incoming light into a wider range, which gives the increased depth of focus, but it comes with the compromise of inducing glare/halos, particularly at night (Figure 3). In my experience, this IOL design produces some of the most bothersome nighttime dysphotopsias in patients, and that may limit its applicability. 3. The Johnson & Johnson Tecnis Symfony increases the depth of focus using diffractive rings, which means that there is increased halo/glare, particularly at night. Beam-shaping EDOF IOLs The Alcon Vivity uses a central 2.2-mm beam-shaping element on the 6-mm optic in order to elongate the depth of focus to about the same range as these other EDOF designs (Figure 4). This IOL was FDA approved in 2020, and it has a good track record of providing a wider range of vision. This design is more dependent on the patient’s pupil size because those patients with larger pupils may get less effect because less of the light entering the eye passes through this focusing zone. In addition, choosing a refractive target may have more dependence on pupil size compared with the other IOL designs. While this IOL does not typically induce night glare/halos, it will limit the contrast, particularly at night. 4. The Alcon Vivity extends the depth of focus using a central beam-shaping element, but this causes loss of contrast, which is especially noticeable at night. In my clinic and surgery center, we offer all these EDOF IOL designs because none is perfect for every patient. We must balance the patient’s needs and desires with their ocular anatomy and biometric data to choose which option will give the best result with the fewest compromises. A video of these surgeries can be found at https://cataractcoach.com/?s=extended . For more information: Uday Devgan, MD, in private practice at Devgan Eye Surgery and a partner at Specialty Surgical Center in Beverly Hills, California, can be reached at devgan@gmail.com ; website: www.CataractCoach.com . Read more about

Alcon Frequently Asked Questions (FAQ)

  • When was Alcon founded?

    Alcon was founded in 1945.

  • Where is Alcon's headquarters?

    Alcon's headquarters is located at 6201 South Freeway, Fort Worth.

  • What is Alcon's latest funding round?

    Alcon's latest funding round is IPO - II.

  • Who are the investors of Alcon?

    Investors of Alcon include Novartis.

  • Who are Alcon's competitors?

    Competitors of Alcon include GlaucoT and 2 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Alcon to Competitors

H
Heidelberg Engineering

Heidelberg Engineering is a medical device company. It had developed the Spectralis Hra+oct, Spectralis Fa_oct, Spectralis Icga+ Oct, Spectralis Hra, Spectralis Fa.Heidelberg Engineering, Inc. develops and distributes state-of-the-art diagnostic solutions for the opthalmologic sector. Products offered by Heidelberg Engineering include Spectralis HRA+OCT, HRT & HEP

I
Intuitive Surgical

Intuitive Surgical is a medical equipment manufacturing company. The company manufactures and markets robotic products to improve clinical outcomes for patients through minimally invasive surgery, most notably with the da Vinci Surgical System. It was founded in 1995 and is based in Sunnyvale, California.

O
Ophthorobotics

Ophthorobotics develops a fully automated system providing safe and highly precise injections into the eye. It offers a robotic injection system for the delivery of intravitreal injections to treat chronic ocular diseases. It was founded in 2014 and is based in Klosters, Switzerland.

L
LensGen

LensGen is developing Juvene, a modular, fluid-optic accommodating intraocular lens which is designed with the potential to permanently restore clear and continuous vision at all distances for patients with cataracts and presbyopia. The lens provides accommodation by mimicking the eye's natural accommodation process to change shape and adjust focus, like the autofocus of a camera. The lens is implanted using current surgical techniques used for traditional intraocular lenses.

GlaucoT Logo
GlaucoT

GlaucoT provides a glaucoma treatment platform to treat glaucoma disease, which causes blindness in advanced stages. It offers a glaucoma treatment device for gamma rhythm entrainment in order to reduce neuroinflammation. The company was founded in 2019 and is based in Istanbul, Turkey.

Medtronic Logo
Medtronic

Medtronic (NYSE: MDT) is a healthcare solutions company. It develops technologies, including implantable mechanical devices, drug and biologic delivery devices, and powered and advanced energy surgical instruments. The company was founded in 1949 and is based in Minneapolis, Minnesota.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.